Licensing Deals in Biotechnology 2021-2026

Understand how biotechnology licensing deals are structured, valued and negotiated using intelligence from 2,157 real-world transactions.

Licensing Deals in Biotechnology provides comprehensive intelligence on 2,157 licensing deals involving biotechnology companies.

Licensing is central to the biotechnology business model, enabling companies to monetize assets and technologies, access development and commercial capabilities, secure new sources of innovation and share the investment and risk required to advance products through development.

The report examines how biotechnology licensing transactions are structured, which companies are most active, where partnering activity is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report provides a practical intelligence and benchmarking resource for teams seeking to understand what is being licensed, who is partnering, how rights and responsibilities are allocated, how financial consideration is structured and how comparable agreements have been negotiated in practice.

It is designed for business development, licensing, search and evaluation, corporate strategy, legal, alliance management and senior management teams involved in evaluating, structuring or negotiating biotechnology licensing transactions.

Understand the biotechnology licensing landscape

The report analyzes licensing dealmaking from 2021 to 2026, including:

• Trends in licensing dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active licensing dealmakers
• Leading licensing deals by disclosed value
• Strategic reasons for entering licensing agreements
• How biotechnology licensing strategies are evolving
• This provides a clear view of where licensing activity is concentrated and which technologies, therapeutic areas, development stages and companies are attracting partnering interest.
• Understand how biotechnology licensing agreements are structured
• Licensing agreements require careful allocation of intellectual property rights, development responsibilities, commercial rights, economics and future control of an asset or technology.

The report provides intelligence to help users examine areas including:

• Rights granted and retained
• Exclusive and non-exclusive licenses
• Geographic and territorial rights
• Field-of-use restrictions
• Intellectual property ownership and control
• Development responsibilities
• Regulatory responsibilities
• Manufacturing and supply arrangements
• Commercialization rights and obligations
• Sublicensing rights
• Governance and decision-making
• Development and commercialization diligence
• Term and termination provisions
• Financial terms where disclosed
• These real-world examples provide valuable reference points for biotechnology companies preparing assets or technologies for licensing discussions.
• Benchmark licensing deal financials
• Financial structure is a critical element of biotechnology licensing.

The report provides access to disclosed financial information associated with individual transactions, enabling users to investigate elements including:

• Upfront payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research and development funding
• Other financial commitments where disclosed
• Leading licensing deals are also ranked by disclosed deal value, enabling users to identify significant precedent transactions and investigate their underlying structures.
• This intelligence can help users place proposed transactions into the context of comparable real-world deals and establish stronger evidence for internal valuation, deal preparation and negotiation.
• Identify prospective licensing partners
• For biotechnology companies seeking to out-license an asset, platform or technology, understanding which organizations have previously entered relevant transactions can provide an important starting point for partner identification.

The report profiles the Top 25 most active licensing dealmakers and provides extensive transaction histories that can help users identify companies with demonstrated interest in particular:

• Therapeutic areas
• Technology types
• Asset classes
• Development stages
• Licensing structures
• This supports targeted business development, search and evaluation, competitor analysis and the identification of organizations with an established appetite for external innovation.
• Learn from real-world licensing contracts
• Where publicly available, the report provides access to underlying licensing contract documents.

These agreements can reveal considerably more than headline deal announcements, allowing users to examine how companies have negotiated and documented provisions including:

• Scope of license
• Exclusivity
• Territory and field
• Intellectual property rights
• Development obligations
• Sublicensing
• Manufacturing and commercialization rights
• Upfront and milestone payments
• Royalty provisions
• Termination and reversion rights
• For biotechnology companies preparing for a licensing transaction, access to real agreement language provides valuable insight into how comparable terms have been structured in practice.
• Comprehensive biotechnology licensing deal directory
• The report includes a comprehensive directory of 2,157 biotechnology licensing deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable transactions, prospective partners and relevant structures when preparing in-licensing or out-licensing strategies.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable assets, technologies, therapeutic areas and development stages.
• Search and Evaluation teams
• Investigate licensing activity across technologies, therapeutic areas and companies to understand external innovation priorities.
• Corporate and Portfolio Strategy teams
• Understand how biotechnology companies use licensing to monetize innovation, access capabilities and advance development programs.
• Legal and Transaction teams
• Review real agreement structures and publicly available contract language to support drafting, negotiation and due diligence.
• Alliance Management teams
• Understand how rights, responsibilities, governance and continuing obligations have been structured across comparable licensing relationships.
• Competitive and Market Intelligence teams
• Track licensing activity by company, technology, therapy area and development phase to identify changing partnering priorities.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying biotechnology licensing intelligence to the customer's own assets, technologies and partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective licensing partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.